

1 R. Brent Wisner, Esq, (SBN: 276023)
rbwisner@wisnerbaum.com
2 Stephanie B. Sherman, Esq. (SBN: 338390)
ssherman@wisnerbaum.com
3 **WISNER BAUM, L.L.P**
4 11111 Santa Monica Boulevard, Suite 1750
5 Los Angeles, CA 90025
6 Telephone: (310) 207-3233
7 Facsimile: (310) 820-7444

Attorneys for Plaintiffs

8 **UNITED STATES DISTRICT COURT**
9 **EASTERN DISTRICT OF CALIFORNIA**

10
11 GRACE NAVARRO and CHATHAM
12 MULLINS, on behalf of themselves, and
13 all others similarly situated, and the
14 general public,

Plaintiffs,

15 v.

16
17 WALGREENS BOOTS ALLIANCE, INC. and
18 DOES 1 to 50, Inclusive,

Defendants.

Civil Action No.

CLASS ACTION COMPLAINT

**CONSUMER FRAUD, BREACH OF
EXPRESS & IMPLIED WARRANTIES,
AND UNJUST ENRICHMENT**

DEMAND FOR JURY TRIAL

TABLE OF CONTENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Page
I. INTRODUCTION	1
II. THE PARTIES	5
III. JURISDICTION AND VENUE	6
IV. GENERAL ALLEGATIONS.....	6
A. WALGREENS DID NOT COMPLY WITH FDA’S TESTING REQUIREMENTS BEFORE SELLING THE PRODUCTS TO THE PUBLIC	7
B. WALGREENS KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE UNDER NORMAL USE, HANDLING, AND STORAGE.....	8
C. WALGREENS KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN OTHER CONSUMER PRODUCTS BUT DID NOT TEST ITS BPO PRODUCTS	11
D. WALGREENS IGNORED FDA’S BENZENE ALERT TO TEST BPO PRODUCTS	11
E. RECENT TESTING FOUND COMMON BPO PRODUCTS, INCLUDING WALGREENS’ PRODUCTS, CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS	12
F. DEFENDANT EXPOSED PLAINTIFFS, THE CLASS, AND THE PUBLIC TO BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR KNOWLEDGE.....	17
G. WALGREENS CONCEALED FROM CONSUMERS ITS FAILURE TO TEST THE BPO PRODUCTS FOR SAFETY	20
H. WALGREENS DID NOT WARN CONSUMERS THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION	21
I. WALGREENS MARKETED AND SOLD BPO PRODUCTS AT RISK OF BENZENE CONTAMINATION TO CHILDREN AND TEENAGERS	21
V. PUNITIVE DAMAGES ALLEGATIONS.....	22
VI. PLAINTIFFS’ SPECIFIC ALLEGATIONS.....	23
VII. CLASS ACTION ALLEGATIONS.....	24
VIII. CAUSES OF ACTION.....	28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

A.	VIOLETION OF CALIFORNIA’S UNFAIR COMPETITION LAW BUS. & PROF. CODE § 17200 <i>et seq.</i> , <i>on Behalf of the California Subclass</i>	28
B.	VIOLETION OF CALIFORNIA’S CONSUMER LEGAL REMEDIES ACT, CAL. CIV. CODE § 1750, <i>et seq.</i> , <i>on Behalf of the California Subclass</i>	30
C.	FALSE ADVERTISING UNDER VARIOUS STATE STATUTES, <i>Individually and on behalf of the California, Hawaii and New York Subclasses</i>	32
D.	DECEPTIVE TRADE PRACTICES UNDER VARIOUS STATE STATUTES, <i>Individually and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i>	35
E.	BREACH OF EXPRESS WARRANTY, <i>Individually and on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington State Subclasses</i>	38
F.	BREACH OF IMPLIED EXPRESS WARRANTY, <i>Individually and on Behalf of the Nationwide Class and on Behalf of the California, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i>	39
G.	UNJUST ENRICHMENT, <i>Individually and on Behalf of the Nationwide Class and on Behalf of the California, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i>	41
IX.	PRAYER FOR RELIEF	41
X.	DEMAND FOR JURY TRIAL	42

1 Plaintiffs, GRACE NAVARRO and CHATHAM MULLINS, on behalf of themselves, the
2 proposed Class and Subclasses (defined below), and the public, brings this Class Action Complaint
3 (“Class Action”) against Defendant, alleging the following upon Plaintiffs’ personal knowledge, or
4 where Plaintiffs lack personal knowledge, upon information and belief, including the investigation of
5 counsel.

6 **I. INTRODUCTION**

7 1. This is a consumer fraud Class Action to redress the economic harms caused by
8 Defendant’s sale of benzoyl peroxide acne treatment drug products (“BPO Products” or “Products”)
9 without warning consumers the BPO Products had unsafe levels of the potent human carcinogen
10 benzene, and that the BPO Products were at risk of degrading further into benzene under normal use,
11 handling, and storage conditions.

12 2. The BPO Products are “drugs” used to treat acne vulgaris (“acne”), formulated with a
13 chemical called benzoyl peroxide (“BPO”), along with other inactive ingredients, to make acne
14 treatment creams, washes, scrubs, and bars. Before being sold to the public, the Products must be
15 made in conformity with current good manufacturing practices and must conform to quality, safety,
16 and purity specifications. Defendant’s BPO Products did not.

17 3. BPO Products should not have benzene, nor degrade into benzene, except under
18 extraordinary circumstances.¹ A drug is “adulterated” if it consists in whole or in part of any filthy,
19 putrid, or decomposed substance, is impure, or mixed with another substance.² Under the Federal
20 Food, Drug and Cosmetic Act, it is a crime to introduce or deliver “into interstate commerce any food,
21 drug, device, tobacco product, or cosmetic that is adulterated or misbranded.”³ If benzene is found in
22 any on-market or post-market Product, the drug is adulterated, unlawful and the drug manufacturer
23 must contact the Food and Drug Administration (“FDA”) initiate a voluntary recall.⁴

24
25 ¹ Food and Drug Administration, *Q3C – Tables and List Guidance for Industry* (2017),
<https://www.fda.gov/media/71737/download>.

26 ² 21 U.S.C. § 351(a)(2011); *see also* § 351(b)-(d) (noting that a lack of purity or mixture with another substance
also renders drug adulterated).

27 ³ 21 U.S.C. § 331(a)(2011).

28 ⁴ Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in
Certain Drugs*, [https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-alerts-drug-manufacturers-
risk-benzene-contamination-certain drugs](https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-alerts-drug-manufacturers-risk-benzene-contamination-certain-drugs) (last visited Feb. 9, 2024).

1 4. Throughout this Complaint, references to federal law and FDA regulation are merely to
2 provide context and are not intended to raise a federal question of law. All claims alleged herein arise
3 out of violations of state law, which in no way conflict, interfere with, or impose obligations that are
4 materially different than those imposed by federal law.

5 5. The BPO Products marketed and sold by Defendant decomposed into benzene
6 rendering them materially different than advertised, *i.e.*, by containing unsafe levels of benzene.
7 Benzene is a known human carcinogen. Studies dating to the 1800s have led to a consensus within the
8 medical and scientific communities that benzene exposure, even in low amounts, increases the risk of
9 blood cancers and other adverse effects.

10 6. In 2023, Valisure, LLC,⁵ an independent, accredited laboratory that has developed
11 analytical methods to test drugs and consumer products for public safety, tested a representative
12 sample of BPO and non-BPO products and found the BPO Products had dangerous levels of benzene,
13 many multiple times higher than allowed in any regulated drug.⁶ Using industry standard gas
14 chromatography and detection by mass spectrometry (“GC-MS”) instrumentation, with selected ion
15 flow tube mass spectrometry (“SIFT-MS”) for detection of benzene released into the air around
16 certain BPO Products, the Products were incubated to temperatures common during consumer use,
17 handling, and storage and sampled for benzene.⁷ Levels as high as 1600 parts per million (ppm) were
18 found in Defendant’s Product, 2.5% Cream.⁸ Unexpectedly, researchers found that benzene was

19
20 ⁵ Valisure is an independent third-party analytical laboratory that is accredited to International Organization for
21 Standardization (“ISO/IEC”) 17025:2017 standards for chemical testing (PJLA Accreditation Number 94238).
22 In response to rising concerns about drug shortages, generics, and overseas manufacturing, Valisure developed
23 and validated methods to test medications and consumer products distributed in the United States. Valisure has
24 tested a variety of drug and consumer healthcare products for benzene including sunscreens, antiperspirants,
25 body sprays, hand sanitizers, and dry shampoos for benzene. Valisure’s testing results submitted to the FDA in
26 its Citizen’s Petitions, were widely publicized in the media leading to numerous recalls of contaminated
27 consumer products. *See* Valisure Citizen’s Petition on Benzoyl Peroxide (March 4, 2024), pp. 6-7, *see also*
28 Valisure Detects Benzene in Sunscreen, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>; Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; *see also* Sandee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021), <https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.

⁶ Valisure FDA Citizen’s Petition on Benzoyl Peroxide (March 6, 2024).

⁷ *Id.*

⁸ *Id.* at 17.

1 released into the surrounding air outside the Products’ containers even when the packaging and
2 containers were closed raising concern for even more inhalation exposures—a particularly pernicious
3 form of exposure to benzene.⁹ For the non-BPO products tested, benzene was not present, or at trace
4 levels below 2 ppm.¹⁰ Valisure filed a FDA Citizen’s Petition on March 5, 2024 demanding an
5 immediate recall of all BPO Products.¹¹ The Petition is pending.¹²

6 7. The high levels of benzene found led Valisure to conduct a stability study on a diverse
7 market sweep of BPO Products and formulations. Valisure’s results show that on-market BPO
8 Products can form over 800 times the conditionally restricted FDA concentration limit of 2 ppm for
9 benzene, and the evidence suggests this problem applies broadly to BPO Products currently on the
10 market.¹³ Valisure concluded that on-market BPO Products appear to be fundamentally unstable and
11 form unacceptably high levels of benzene when handled or stored at temperatures the Products will be
12 exposed to during expected use and handling by consumers.¹⁴

13 8. Although the BPO Products have been found to have benzene, Defendant never listed
14 benzene among the its Products’ ingredients, or anywhere on the Products’ labels, containers,
15 advertising or on Defendant’s websites. Defendant never warned anyone the Products had benzene or
16 were at risk of benzene contamination.

17 9. Defendant knew or should have known its BPO Products contain and/or degraded into
18 benzene when exposed to expected consumer use, handling, and storage conditions. BPO is known,
19 within the scientific community (but not among consumers) to degrade into benzene according to the
20

21 _____
22 ⁹ *Id.* at 23.

23 ¹⁰ *Id.* at 15 (“76 non-BPO products had no detectable benzene or values below 0.1ppm. 6 non-BPO products
24 contained traces of benzene below 2 ppm, which could be due to various inactive ingredients used in consumer
25 products that have been theorized to contain trace benzene”); *see also* Valisure, LLC,
<https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March
26 6, 2024).


27 ¹¹ Valisure’s Citizen Petition on Benzene in Benzoyl Peroxide Products (March 5, 2024), *available at*:
<https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March
28 7, 2024).

¹² Valisure’s Citizen’s Petition was still pending as of this Class Action’s filing.

¹³ Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and
Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide>
(last visited March 6, 2024).

¹⁴ *Id.*

1 mechanism below:¹⁵



10 10. Defendant misled the Plaintiffs, the putative Classes, and the public by representing its
 11 BPO Products only had the ingredients listed on the labels, packaging, containers, and on its website.
 12 Defendant misled the Plaintiffs, the putative Classes, and the public by representing the BPO Products
 13 were safe while concealing material health and safety information known to them, *e.g.*, that the BPO
 14 Products degraded to benzene, or were contaminated with benzene. Defendant misled Plaintiffs, the
 15 putative Classes, and the public by giving the BPO Products long expiration dates of 2-3 years,
 16 leading consumers to believe the Products were safe for use for years when Defendant knew or should
 17 have known the Products degraded into benzene much sooner and were likely already contaminated
 18 by the time the Products were first used by the consumer.

19 11. Defendant's statements and omissions of material health and safety information are
 20 prohibited deceptive trade practices and false and deceptive advertising. Defendant's statements about
 21 the Products were false, misleading, unsubstantiated, untruthful, and blatantly deceptive. Even more
 22 egregious was Defendant unreasonably placed Plaintiffs, the California Class, and the public at risk of
 23 exposure to benzene, and at increased risk of cancer, without their knowledge and consent.

24 12. Because of the Defendant's misconduct and consumer deception, the Plaintiffs and the

25 _____
 26 ¹⁵ The disposition of benzoyl peroxide to form benzene. Benzoyl peroxide is known to thermally decompose to
 27 form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with
 28 liberation of carbon dioxide. The phenyl radicals can then produce benzene. *See* Shang-Hao Liu, et al,
Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III,
 THERMOCHIMICA ACTA, Volume 605, Pages 68-76, (2015), ISSN 0040-603,
<https://www.sciencedirect.com/science/article/pii/S004060311500057X>.

1 putative Classes were economically harmed, as they bought Products they otherwise would have
2 never bought. They were also physically harmed by being exposed to a known human carcinogen.

3 13. This Class Action is necessary to redress the economic harms caused to the Plaintiffs
4 and Class members who bought the Products believing them to be safe. This Class Action is further
5 necessary to expose Defendant's ongoing consumer fraud and to enjoin Defendant from continuing
6 their misconduct to protect consumers and the public.

7 14. Plaintiffs bring this Class Action individually, and on behalf of those similarly situated,
8 and seek to represent a California Class of consumers who bought the Products. Plaintiffs seek
9 damages, reasonable attorneys' fees and costs, interest, restitution, and all other equitable relief,
10 including an injunction and disgorgement of all benefits and profits Defendant received from their
11 misconduct.

12 **II. THE PARTIES**

13 15. Plaintiff Grace Navarro is a California resident, located in Fresno County, who bought
14 BPO Products including Walgreens' Maximum Strength Acne Foaming Wash for her pores and
15 breakouts and used it from June 2022 to September 2022. Plaintiff has suffered economic damages
16 and a result of Defendant's violations of the state laws alleged herein. Plaintiff would never have
17 purchased Defendant's BPO Products had Defendant warned about the presence of benzene or that the
18 Products could degrade into benzene.

19 16. Plaintiff Chatham Mullins is a Massachusetts resident, located in Suffolk County, who
20 bought BPO Products including Walgreens' Daily Creamy Benzoyl Peroxide Acne Face Wash for her
21 acne blemishes and used it from 2005 to 2023. Plaintiff has suffered economic damages and a result
22 of Defendant's violations of the state laws alleged herein. Plaintiff would never have purchased
23 Defendant's BPO Products had Defendant warned about the presence of benzene or that the Products
24 could degrade into benzene.

25 17. Defendant Walgreens Boots Alliance, Inc. ("Walgreens") is a citizen of Illinois and
26 Delaware with its principal place of business in Deerfield, Illinois. Walgreen's Products include, inter
27 alia: (1) Daily Creamy Benzoyl Peroxide Acne Face Wash and (2) Maximum Strength Acne Foaming
28 Wash. At all relevant times, Walgreens conducted business and derived substantial revenue from its

1 manufacturing, advertising, marketing, distributing, and selling of the Products within the State of
2 California.

3 18. Defendant and its agents promoted, marketed, and sold the Products in California and in
4 this District. The unfair, unlawful, deceptive, and misleading advertising and labeling of the Products
5 were prepared and/or approved by Defendant and its agents and were disseminated by Defendant and
6 its agents through statements, labeling, and advertising containing the misrepresentations alleged and
7 disseminated uniformly to Plaintiffs and the Subclass members through Defendant's advertising,
8 packaging, containers, and via its websites and social media.

9 **III. JURISDICTION AND VENUE**

10 19. This Court has jurisdiction over this matter because the amount in controversy exceeds
11 \$5 million satisfying 28 U.S.C. § 1332(d)(2) for subject matter jurisdiction. This Court has
12 supplemental jurisdiction over any state law claims under 28 U.S.C. § 1367.

13 20. Venue is proper in the Eastern District of California under 28 U.S.C. § 1391(b) because
14 a substantial part of the events or omissions giving rise to the claims occurred in this District.

15 21. This Court has personal jurisdiction over the Defendant because Defendant transacts
16 business in California, including in this District, has substantial aggregate contacts with the State of
17 California and in this District, engaged in misconduct that has and had a direct, substantial, reasonably
18 foreseeable, and intended effect of injuring people in California and in this District, and Defendant
19 purposely availed itself of the benefits of doing business in California, and in this District. Moreover,
20 Plaintiffs' claim arises out of and relates to the Defendant's actions and contacts with the State of
21 California.

22 22. To the extent applicable, the Court also has pendant personal jurisdiction over claims
23 alleged against Defendant that involve the same common nucleus of facts and actions that give rise to
24 Plaintiffs' claims that otherwise have proper personal jurisdiction within this Court.

25 **IV. GENERAL ALLEGATIONS**

26 23. Fifty million Americans suffer from acne annually.¹⁶ Acne is the most common skin
27
28

¹⁶ American Association of Dermatology, <https://www.aad.org/media> (visited October 24, 2023).

1 condition in the United States with a prevalence among adolescents of almost 95 percent.¹⁷ Acne can
2 begin as early as age seven and, for some, can persist through adulthood and into ages 50s and 60s.¹⁸
3 Millions of acne sufferers seek treatment every year making it a billion-dollar industry and a key
4 business segment for Defendant Walgreens, who sells BPO Products under its private label.

5 24. Defendant Walgreens dominates the drug and consumer health care products' markets
6 year after year and is among America's top Fortune 50 publicly traded companies. Walgreens
7 markets itself as a pharmacy and retail leader serving millions of customers and patients every day,
8 with a 170-year heritage of caring for communities.¹⁹ Walgreens claims it is a trusted, global
9 innovator in retail pharmacy with approximately 13,000 locations across the U.S., Europe, and Latin
10 America. Defendant earned 139.1 billion dollars during fiscal year 2023.²⁰ Walgreens heavily markets
11 its commitment to environmental concerns stating it is determined to protect the planet through
12 internal programs and by engaging suppliers on environmental issues to reduce emissions and waste
13 and were committed to sustainability and lessening its environmental impact.²¹

14 **A. WALGREENS DID NOT COMPLY WITH FDA'S TESTING REQUIREMENTS**
15 **BEFORE SELLING THE PRODUCTS TO THE PUBLIC**

16 25. Despite its public affirmations of concern for consumers Walgreens did not adequately
17 test its BPO Products before selling them to the public. Defendant's BPO Products are "drugs"
18 regulated by the FDA. As with any regulated drug, Defendant must follow current good
19 manufacturing practices ("CGMPs"), have scientifically sound specifications, and must have test
20 procedures and processes to ensure the drug's components (active and inactive ingredients), and
21 finished products are safe. Both raw ingredient materials and finished batches must be tested before
22 released to the public to confirm they meet specifications for identity, strength, quality, and purity.²²
23

24 ¹⁷ JL Burton et al., *The prevalence of acne vulgaris in adolescence*, BR J DERMATOL,(1971);85(2):119–126.

25 ¹⁸ *Id.*

26 ¹⁹ Walgreens Alliance Boots, Inc, <https://www.walgreensbootsalliance.com/about-us>.

27 ²⁰ Press Release. Walgreens Boots Alliance, Inc. (Oct. 12, 2023). *Walgreens Boots Alliance, Inc. Fiscal Year 2023 Earnings*, <https://www.walgreensbootsalliance.com/news-media/press-releases/2023/walgreens-boots-alliance-reports-fiscal-year-2023-earnings> (visited November 1, 2023).

28 ²¹ Walgreens Boots Alliance, Inc. *Environmental, Societal, & Governance*, <https://www.walgreensbootsalliance.com/environmental-social-governance/healthy-planet> (last visited November 1, 2023).

²² 21 C.F.R. § 211.84 (1978); *see also* 21 C.F.R. § 211.160 (1978).

1 If testing results of the raw materials or finished product do not conform with the specifications, the
2 product cannot be sold to the public. Defendant must also re-test any Products subject to
3 deterioration.²³ Any Products not made in conformity with the CMGPs is considered “adulterated”
4 under 501(a)(2)(B) of the Food, Drug, and Cosmetic Act.²⁴

5 26. Defendant must also do stability testing to understand the “shelf life” of the Products
6 and to assign an expiration date. It is well known that certain chemical ingredients can degrade or
7 change because of environmental, and storage conditions such as light, moisture, temperature, and
8 humidity, or because of the passage of time. The stability testing should cover all expected distributor
9 and consumer storage, handling, and use conditions and must be done using “reliable, meaningful, and
10 specific test methods.”²⁵ If stability testing finds a drug product is not stable under expected storage or
11 use conditions, degrades, or create toxic byproducts, the product cannot be sold to the public.

12 27. The CGMPs and stability test requirements are there to ensure drug products are safe
13 for public use. These are the minimum requirements. Because the drug manufacturers are largely self-
14 regulated, the FDA must rely on drug manufacturers, the public, and concerned citizens to report
15 unsafe drugs. The FDA cannot force a drug manufacturer to recall a contaminated drug.²⁶

16 **B. WALGREENS KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS**
17 **DEGRADED TO BENZENE UNDER NORMAL USE, HANDLING, AND**
18 **STORAGE**

19 28. Defendant knew or should have known the BPO Products degrade to benzene when
20 exposed to heat. Defendant knew that, because of the chemical nature of the active and inactive
21 ingredients, including BPO, the BPO Products were not stable and would degrade when exposed
22 normal and expected use, handling, and storage conditions.


23 _____
²³ 21 C.F.R. § 211.160(b)(1)(1978).

24 ²⁴ 21 C.F.R. § 225.1 (1976). Under 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act a drug is
25 considered “adulterated” (poorer in quality by adding another substance) if the methods used in, or the facilities
26 or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or
27 administered in conformity with CGMP; *see also* Food and Drug Administration, *Facts About the Current*
Good Manufacturing Practices (CGMP); [https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp)
28 [about-current-good-manufacturing-practices-cgmp](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp) (last visited Feb. 11, 2024).

²⁵ 21 CFR 211.166.

²⁶ Food and Drug Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*;
[https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp)
[practices-cgmp](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp) (last visited Feb. 11, 2024).

29. It is well known that BPO degrades to benzene when exposed to heat over time. This process was first reported in the scientific literature as early as 1936.²⁷ BPO degrades into benzene according to the mechanism below.²⁸



30. The degradation of BPO to benzene was known or should have been known to the Defendant, who promote themselves as expending substantial sums of money and resources to science and research. Defendant marketed themselves as mass merchandisers of quality drug and healthcare products. Defendant employed high-level scientists, chemists, and researchers to formulate and/or decide which drug products it will privately label and sell for public use. Defendant with these resources and expertise were aware of the well-known chemical processes that degrade their BPO Products into benzene when exposed to common use temperatures and conditions.

31. Defendant further knew or should have known that specific ingredients derived from hydrocarbons increased the risk the BPO Products would yield benzene.²⁹ At-risk ingredients include carbomers, mineral spirits, and other petroleum derived substances. These ingredients are red flags for risk of benzene contamination. The FDA published guidance in 2022 urging the industry to

²⁷ H. Erlenmeyer and W. Schoenauer, *Über die thermische Zersetzung von Di-acyl-peroxyden*, HELV. CHIM. ACTA, 19, 338 (1936), <https://onlinelibrary.wiley.com/doi/10.1002/hlca.19360190153> (last visited Feb. 5, 2024).

²⁸ Benzoyl peroxide is known to thermally decompose to form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of carbon dioxide. The phenyl radicals can then produce benzene. See Shang-Hao Liu et al., *Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, (2015), Pages 68-76, ISSN 0040-6031, <https://www.sciencedirect.com/science/article/pii/S004060311500057X> (last visited Feb. 5, 2024).

²⁹ Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*.

1 reformulate drug products at risk of benzene contamination.³⁰ The FDA’s alert highlighted
2 ingredients made from hydrocarbons, including carbomers (thickening agents), urging drug
3 manufacturers to test products containing them for benzene contamination.³¹ Many BPO Products
4 have hydrocarbons and carbomers but none have been recalled due to benzene contamination.

5 32. Defendant knew or should have known through their own research, development,
6 formulation, evaluation, selection, and testing of BPO Products whether they were chemically and
7 physically stable. Defendant was required not only to adequately test the BPO Products for safety and
8 stability before selling them to the public, but also to monitor their internal practices, processes, and
9 specifications to make sure they kept pace with science and emerging methodologies. Defendant
10 knew or should have known from expiration and stability studies examining the “shelf life” of the
11 BPO Products, the chemical changes took place because of normal and expected environmental, use,
12 and storage conditions.

13 33. Defendant knew or should have known the BPO Products would be handled, used, and
14 stored by distributors, sellers, and consumers under various temperatures that affect chemical stability.
15 Defendant knew or should have known the BPO Products would travel by commercial carriers and
16 distributors in varying storage conditions and would be stored by consumers in handbags, backpacks,
17 bathrooms, showers, lockers, and in vehicles during warm months where the BPO Products would be
18 exposed to heat. Defendant knew or should have known consumers would apply the benzene
19 contaminated BPO Products to their faces and bodies and would also use the BPO Products in heated
20 showers as scrubs and washes. Defendant knew or should have known the BPO Products would be
21 used and applied to the skin at normal body temperatures, and elevated temperatures following
22 showers or baths, after physical activity, and after the BPO Products sat in warm temperatures or hot
23 vehicles.

24 34. These storage, use, and handling conditions were known or should have been known to
25 Defendant before the BPO Products were marketed and sold to Plaintiffs, the Class, and Subclass
26

27 ³⁰ Food and Drug Administration. *Reformulating Drug Products That Contain Carbomers*
28 *Manufactured With Benzene* (December 27, 2023), <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene>.

³¹ *Id.*; see also December 22, 2022 FDA Alert at 1.

1 members. Defendant knew or should have known the BPO Products degrade to benzene under these
2 conditions exposing consumers to benzene. Defendant further knew or should have known that,
3 because of the known degradation of BPO to benzene, their BPO Products were contaminated with
4 benzene by the time they reached consumers, but they sold them to Plaintiffs, the Class, the Subclass,
5 and the public anyway, without warning of the risk of exposure. Moreover, the 2–3-year shelf life
6 printed on the BPO Products told consumers they were safe for use for years, when they were not.

7 **C. WALGREENS KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND**
8 **IN OTHER CONSUMER PRODUCTS BUT DID NOT TEST ITS BPO**
9 **PRODUCTS**

10 35. Defendant was aware or should have been aware of benzene contamination in other on-
11 market drug and healthcare products when they marketed and sold the BPO Products to Plaintiffs, the
12 Class, the Subclass, and the public but did not test the BPO Products for benzene contamination.

13 36. In 2020, the FDA started working with companies to identify benzene in products,
14 which resulted in product recalls of hand sanitizers, sunscreens, and deodorants. In 2021, an
15 independent chemical analysis by Valisure of hundreds of sunscreens and after-sun care products from
16 69 brands found 27 percent of the batches had significant levels of benzene above the FDA 2 ppm
17 limit.³² Johnson and Johnson’s Aveeno and Neutrogena sunscreen lines sold by Target were among
18 the most benzene contaminated products and were recalled.³³ CVS’s private brand after-sun care
19 products were also highly contaminated with benzene. By 2021, Defendant was well aware of
20 benzene contamination issues in its competitor’s products but ignored the reports and continued to
21 advertise and sell the BPO Products without testing them for benzene.

22 **D. WALGREENS IGNORED FDA’S BENZENE ALERT TO TEST BPO**
23 **PRODUCTS**

24 37. In 2022, the FDA issued a safety alert warning drug manufacturers of the risk of
25 benzene contamination in certain drug products and drug components. The FDA reiterated the risk
26 benzene exposure poses to public health and the drug manufacturers’ obligations to test drug products

27 ³² Valisure Citizen Petition on Benzene in Sunscreen and After-sun Care Products, May 24, 2021.

28 ³³ Press Release. (July 14, 2021), Johnson & Johnson Consumer Inc. Johnson & Johnson Consumer Inc.
Voluntarily Rec of Specific Neutrogena and Aveeno Aerosol Sunscreen Products Due to the Presence of Benzene.

1 under the U.S. Code of Federal Regulations, Title 21:

2 FDA reminds manufacturers they are required to establish scientifically
3 sound and appropriate specifications and test procedures to assure drug
4 components (active and inactive ingredients) and finished drug products
5 conform to appropriate quality specifications (21 C.F.R. 211.84, 21 C.F.R.
6 211.160). This includes testing of raw materials and finished batches (21
7 C.F.R. 211.165) prior to release to ensure they meet appropriate
8 specifications for identity, strength, quality, and purity.³⁴

9 38. The FDA warned drug manufacturers that any drug products or components at risk of
10 benzene contamination should be tested, and any batches with benzene above 2 ppm should not be
11 released to the public.³⁵ The FDA further warned that, if any drug or drug component was subject to
12 deterioration, drug manufacturers must have re-testing procedures in place to ensure continued purity
13 and stability. The FDA recommended risk assessments to evaluate the possibility of benzene
14 contamination in the drug products or components.³⁶ If any drug product in circulation was found to
15 have benzene over 2ppm, the FDA directed that drug manufacturers contact the FDA to discuss a
16 voluntarily recall.³⁷

17 39. To date, none of the Defendant's Products have been recalled due to benzene
18 contamination.

19 **E. RECENT TESTING FOUND COMMON BPO PRODUCTS, INCLUDING**
20 **WALGREENS' PRODUCTS, CONTAIN DANGEROUS LEVELS OF BENZENE**
21 **IN EXCESS OF REGULATORY LIMITS**

22 40. Testing by Valisure in 2023 found common acne treatment products formulated with
23 BPO are not only contaminated with benzene but have levels dangerous to public health. Valisure is
24 an accredited independent laboratory who has developed validated analytical methods³⁸ to test drugs
25 and consumer products to address rising concerns about public safety. Valisure has tested a wide
26 variety of drugs and products for benzene including sunscreens, antiperspirants, hand sanitizers, and
27 dry shampoos. Their work has led to widely publicized product recalls protecting the public from

28 ³⁴ Federal Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*, 1.

³⁵ *Id.*, 3.

³⁶ *Id.*

³⁷ *Id.*, 2.

³⁸ Valisure's test methods largely mirror those utilized by FDA's own "Drug Quality Sampling and Testing" ("DQST") Program. Valisure FDA Citizen's Petition at 4.

1 dangerous and carcinogenic consumer products.³⁹

2 41. In 2023, Valisure tested 175 finished acne treatment products to determine whether any
3 had benzene. Of the 175 products tested, 99 were formulated with BPO, 58 had active ingredients
4 (either individually or in combination) of salicylic acid, sulfur, adapalene, azelaic acid, niacinamide
5 and zinc, and 18 had no drug ingredients.⁴⁰ 83 of the BPO Products were purchased over the counter
6 from major retailers and 16 were prescription products purchased from licensed wholesalers.⁴¹ The
7 BPO Products included popular Products: Proactiv 2.5% BPO Cream, Target Up & Up 2.5% BPO
8 Cream, Equate Beauty 10% BPO Cream, Equate BPO Cleanser, Neutrogena 10% BPO Cleanser,
9 Clearasil 10% BPO Cream, CVS Health 10% BPO Face Wash, Walgreens 10% BPO Cream, La
10 Roche Posay BPO Cream, and Clean & Clear 10% BPO Lotion.

11 42. Valisure used three incubation temperatures to evaluate the effects of common
12 distributor and consumer use, handling, and storage conditions on benzene formation. 37°C/98.6°F
13 was used for human body temperature, 50°C/122°F was used to evaluate shelf-life performance as an
14 accelerated stability testing temperature used by the pharmaceutical industry,⁴² and 70°C/158°F to
15

16
17 ³⁹ See Valisure May 24, 2021 Citizen Petition on Benzene in Sunscreen and After-sun Care Products,
18 <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>); Valisure’s Citizen
19 Petition on Hand Sanitizer Products Containing Benzene Contamination (filed March 24, 2021),
20 <https://www.regulations.gov/document/FDA-2021-P-0338-0001>), Valisure’s Citizen Petition on Benzene in
21 Sunscreen and After-sun Care Products (filed May 24, 2021), <https://www.regulations.gov/document/FDA-2021-P-0497-0001>), Valisure’s Citizen Petition on Benzene in Body Spray Products (filed November 3, 2021,
22 <https://www.regulations.gov/document/FDA-2021-P-1193-0001>), Valisure’s Citizen Petition on Benzene in
23 Dry Shampoo Products (filed October 31, 2022), <https://www.regulations.gov/document/FDA-2022-P-2707-0001>) see also CNET, Dry Shampoo Recall: What Is Benzene and Which Brands Are Affected
24 <https://www.cnet.com/health/personal-care/dry-shampoo-recall-what-is-benzene-and-which-brands-are-affected/> (identifying 19 types of dry shampoo have been recalled due to benzene content); Ryan Basen,
25 Medpage Today, After Valisure Petition, Ol’ Dirty Benzene Forces Another Recall (November 30, 2021),
26 <https://www.medpagetoday.com/special-reports/exclusives/95929> (“After Valisure Petition, Ol’ Dirty Benzene Forces Another Recall”); Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk
27 Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; see also Sandee LaMotte, CNN, Antiperspirant
28 recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021),
<https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.


⁴⁰ See Valisure Citizen’s Petition on Benzoyl Peroxide (March 4, 2024).

⁴¹ *Id.*


⁴² Ghimire, Prakash et al., *Guidelines on Stability Studies of Pharmaceutical Products and Shelf Life Estimation*. INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY AND BIOTECHNOLOGY, (2020). 06. 15-23. 10.38111/ijapb.20200601004.

1 model storage in a hot vehicle.⁴³ The BPO Products were incubated at 37°C for four weeks and 50°C
 2 for three weeks and benzene concentration was measured at certain time intervals using GC-MS.
 3 Benzene findings were plotted in real time and reported in parts per million (“ppm”). The results
 4 below were submitted to the FDA in Valisure’s March 5, 2024 Citizen’s Petition on Benzoyl
 5 Peroxide.⁴⁴

6 **4A**



14 **4B**




26 ⁴³ Grundstein A, Meentemeyer V, Dowd J. *Maximum vehicle cabin temperatures under different meteorological conditions*. Int J Biometeorol. 2009 May;53(3):255-61. doi: 10.1007/s00484-009-0211-x. Epub 2009 Feb 21. PMID: 19234721.


28 ⁴⁴ Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


4C



4D




4E




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


4F



4G



4H



43. Valisure found the BPO formulated products were not chemically stable and yielded benzene at levels well over 2 ppm, the maximum amount allowed in any U.S. regulated drug. Some of the benzene levels were 800 times higher than 2 ppm reaching as high as 1700 ppm.⁴⁵ The

⁴⁵ *Id.*

1 concentration of BPO in the Products did not influence the benzene levels, e.g., Target's Up & Up
2 BPO Lotion and Proactiv's 10% BPO Cream yielded similar benzene results in the range of 600 ppm.
3 Unexpectedly, Valisure found that benzene vapors leaked from some of the tested Products'
4 packaging contaminating the surrounding air even when the packaging was closed raising concern for
5 additional inhalation exposures.⁴⁶

6 44. Valisure concluded that all on-market BPO acne formulations are fundamentally
7 unstable and form unacceptably high levels of benzene under normal use, handling, and storage
8 temperatures, but no such evidence was observed for acne treatment products not formulated with
9 BPO.⁴⁷ The finding that additional benzene leaked into the surrounding air from the products'
10 containers means the total consumer benzene exposure would be even more dangerous than the levels
11 reported.

12 45. Valisure filed a Citizen's Petition on Benzoyl Peroxide on March 5, 2024⁴⁸ with the
13 FDA requesting the FDA Commissioner to immediately demand a recall of all BPO Products
14 formulated with BPO and further to require that drug manufacturers do independent chemical
15 verification. The Petition is pending.

16 **F. DEFENDANT EXPOSED PLAINTIFFS, THE CLASS, AND THE PUBLIC TO**
17 **BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR**
18 **KNOWLEDGE**

19 46. Although benzene has been found in the BPO Products and released into the
20 surrounding air from the packaging, Defendant did not list benzene among the Products' ingredients,
21 on the Products' label or container, or anywhere in their advertising or on their websites. Defendant
22 did not (and still do not) warn that the Products contain benzene, are at risk of benzene contamination,
23 or that the product could cause consumers to be exposed to benzene even when sealed.

24 47. Benzene is a carcinogen that has been among the most studied toxins over the last 100
25 years due to its wide use during the industrial revolution, extreme danger, and known ability to cause
26 cancer and death in humans and animals. The medical literature linking benzene to blood cancers is

27 _____
28 ⁴⁶ *Id.*

⁴⁷ *Id.*

⁴⁸ As of the date of filing this Class Action, Valisure's FDA Petition is still pending.

1 vast dating to the 1930s.⁴⁹ Benzene is the foundation component for many chemicals used to make
 2 plastics, resins, synthetic fibers, paints, dyes, detergents, drugs, and pesticides. In the past, benzene
 3 was widely used as a solvent in industrial paints, paint removers, adhesives, degreasing agents,
 4 denatured alcohol, and rubber cements. Benzene use has declined due to the proliferation of worker
 5 studies and an ever-growing body of evidence confirming benzene's contribution to blood cancers.

6 48. Benzene has no known safe level of exposure.⁵⁰ Benzene causes central nervous system
 7 depression and destroys bone marrow, leading to injury in the hematopoietic system.⁵¹ The
 8 International Agency for Research on Cancer ("IARC") classifies benzene as a "Group 1 Carcinogen"
 9 that causes cancer in humans, including acute myelogenous leukemia ("AML").⁵² AML is the
 10 signature disease for benzene exposure with rates of AML particularly high in studies of workers
 11 exposed to benzene.⁵³

12 49. Benzene exposure is cumulative and additive. There is no safe level of exposure to
 13 benzene, and all exposures constitute some risk in a linear, if not supralinear, and additive fashion."⁵⁴

14 50. The Agency for Toxic Substances and Disease Registry's ("ATSDR") "Tox Facts" for
 15 benzene warns that people can be exposed to benzene vapors from benzene-containing products and
 16 that benzene harms the blood marrow, causing leukemia and anemia, and affects the immune system
 17 leaving victims vulnerable to infection.⁵⁵

19 ⁴⁹ See Hamilton A., *Benzene (benzol) poisoning*, ARCH PATHOL, (1931):434-54, 601-37; Hunter FT, *Chronic*
 20 *exposure to benzene (benzol). Part 2: The clinical effects*. J. IND. HYG TOXICOL, (1939):21 (8) 331-54;
 21 Mallory TB, et al., *Chronic exposure to benzene (benzol). Part 3: The pathological results*. J. IND. HYG
 22 TOXICOL, (1939):21 (8) 355-93; Erf LA, Rhoads CP., *The hematological effects of benzene (benzol)*
 23 *poisoning*. J. IND. HYG TOXICOL, (1939):21 421-35; American Petroleum Institute, *API Toxicological*
 24 *Review: Benzene*, NEW YORK, (1948); Infante PF, Rinsky RA, Wagoner JK, et al., *Leukemia in benzene*
 25 *workers*, LANCET, (1977);2 (8028): 76-78.

26 ⁵⁰ Harrison R, Saborit, J., *WHO Guidelines for Indoor Air Quality – Selected Pollutants*, (2010); see also
 27 Smith, Martyn T. (2010). *Advances in Understanding Benzene Health Effects and Susceptibility. Annual*
 28 *Review of Public Health.*, (2010) Vol. 31:133-148.

⁵¹ FDA Toxicological Data for Class 1 Solvents, Appendix 4, *Benzene*,
<https://www.fda.gov/media/71738/download>.

⁵² International Agency for Research on Cancer. *Benzene, IARC Monographs on the Evaluation of*
Carcinogenic Risks to Humans, Volume 120, LYON, France: World Health Organization, (2018).

⁵³ American Cancer Association, *Benzene and Cancer Risk*, <https://www.cancer.org/cancer/risk-prevention/chemicals/benzene.html> (last visited October 20, 2023).

⁵⁴ Smith, Martyn T., *Annual Review of Public Health*, *ADVANCES IN UNDERSTANDING BENZENE*
HEALTH EFFECTS AND SUSCEPTIBILITY (2010) Vol. 31:133-148.

⁵⁵ Agency for Toxic Substances and Disease Registry, *Benzene – Tox Facts*, CAS # 71-43-2.

1 51. According to the FDA, benzene in small amounts over long periods of time can
2 decrease the formation of blood cells and long-term exposure through inhalation, oral intake, and skin
3 absorption may result in cancers such as leukemia and other blood disorders.⁵⁶

4 52. Benzene is a major industrial chemical made from coal and oil that is heavily regulated
5 by the EPA as an important environmental pollutant that negatively affects the soil, air, and
6 groundwater. Waste and air emissions containing benzene are considered hazardous waste. The coal,
7 oil, paint, and chemical industries are heavily regulated due to the emission of carcinogens including
8 benzene from refining and other industries processes involving benzene and benzene byproducts,
9 which can end up in the air, water, and food supply.

10 53. Benzene is heavily regulated to protect public health and should not be in drug
11 products, especially ones such as acne treatment that are used daily by children and teenagers for
12 many years. The FDA drug guidelines specify that benzene must not be used to make drugs products
13 because of the unacceptable toxicity and deleterious environmental effects.⁵⁷ The FDA allows one
14 limited exception – where the use of benzene in a drug product is unavoidable to produce a drug
15 product with a significant therapeutic advance. In that instance, benzene must be restricted to two
16 parts per million (ppm).⁵⁸ Defendant’s BPO Products do not meet this rare exception.

17 54. Benzene is heavily regulated in the workplace. The U.S. Occupational Safety and
18 Health Administration (“OSHA”) set an eight-hour exposure standard of 1 ppm.⁵⁹ The National
19 Institute for Occupational Safety and Health (“NIOSH”) established a recommended exposure level
20 (REL) of 0.1 ppm (15-minute ceiling limit). Subsequent exposure studies known as the “China
21 studies” confirmed cancer at levels below 1 ppm.⁶⁰ The benzene levels created from Defendant’s
22 BPO Products are many times higher than the levels reported in these worker studies and the
23

24 ⁵⁶ Federal Drug Administration. (June 9, 2022). *Frequently Asked Questions*: <https://www.fda.gov/drugs/drug-safety-and-availability/frequently-asked-questions-benzene-contamination-drugs>.

25 ⁵⁷ Food and Drug Administration, *Q3C – Tables and Lists Guidance for Industry*,
<https://www.fda.gov/media/71737/download> (last visited September 26, 2023).

26 ⁵⁸ *Id.*

27 ⁵⁹ OSHA. Occupational exposure to benzene: Final rule. Fed. Reg. 1987;52-34460-578.

28 ⁶⁰ See Lan Q, Zhang L et al., *Hematotoxicity in Workers Exposed to Low Levels of Benzene*, SCIENCE, (December 3, 2004); Costa-Amaral I, V. B. L., *Environmental Assessment and Evaluation of Oxidative Stress and Genotoxicity Biomarkers Related to Chronic Occupational Exposure to Benzene*, INT J ENVIRON RES PUBLIC HEALTH, (2019) Jun; 16(12): 2240.

1 acceptable limits set by regulators.

2 55. Benzene can also pass from the mother's blood to a developing fetus causing the baby
3 to be exposed to benzene.⁶¹ Animal studies have shown low birth weights, delayed bone formation,
4 and damage to the bone marrow of developing offspring when pregnant animals breathed benzene.⁶²

5 56. Plaintiffs and the Class were exposed to benzene from the BPO Products by inhalation
6 and dermal absorption. Benzene can be absorbed into the body via inhalation, skin absorption,
7 ingestion, and/or eye contact.⁶³ Plaintiffs and the Class applied the BPO Products to areas of the skin
8 including the face, neck, chest, and back one to three times per day and used the BPO Products as
9 washes or scrubs in heated showers. Plaintiffs and the Class were also exposed to benzene leaked
10 from contaminated BPO Products.

11 **G. WALGREENS CONCEALED FROM CONSUMERS ITS FAILURE TO TEST**
12 **THE BPO PRODUCTS FOR SAFETY**

13 57. Defendant Walgreens' BPO Products degrade to benzene under normal and expected
14 handling, use, or storage but it did not warn the public about the risk of benzene contamination or the
15 health risks of exposure. Instead, Defendant made broad sweeping claims that its BPO Products were
16 safe, and that it was a company concerned about its consumers and the environment leading
17 consumers to believe it would not sell a benzene contaminated Product.⁶⁴

18 58. Defendant's affirmations of safety and responsibility, misrepresentations, and omissions
19 of material health and safety information misled Plaintiffs, the Class, the Subclass, and the public
20 regarding the safety, stability, and quality of the BPO Products. Defendant's affirmations of safety and
21 responsibility gave Plaintiffs, the Class, the Subclass, and the public a false sense of safety.
22 Defendant made these statements uniformly to Plaintiffs, the Class, the Subclass, and the public.
23 Defendant's statements were false, misleading, unsubstantiated, and blatantly deceptive.

24 ///

25 ///

26 _____
27 ⁶¹ *Id.*

28 ⁶² *Id.*

⁶³ Centers for Disease Control and Prevention, *The National Institute for Occupational Safety and Health Pocket Guide to Chemical Hazards, Benzene Exposure Limits*, <https://www.cdc.gov/niosh/npg/npgd0049.html>.

⁶⁴ *Id.*

H. WALGREENS DID NOT WARN CONSUMERS THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION

59. Defendant Walgreens represented to the Plaintiffs, the Class, the Subclass, and the public, that the BPO Products had only the ingredients listed on the Products' label, container, advertising, and packaging. Defendant never identified benzene anywhere on the Products, or labels, containers, or packaging. Defendant never disclosed benzene, or that the Product was at risk of degradation to benzene on any of its websites or Product containers.

60. Defendant's statements about the BPO Products' ingredients were false, deceptive, and misleading. Defendant's statements were meant to convey to Plaintiffs, the Class, the Subclasses, and the public the Products were safe and did not contain carcinogens such as benzene. Defendant made these statements uniformly to consumers and specifically omitted benzene from all advertising, labeling, and packaging when they knew or should have known the statements were false, misleading, and deceptive. Reasonable consumers, relying on Defendant's statements reasonably believed the BPO Products were safe and did not contain benzene.

I. WALGREENS MARKETED AND SOLD BPO PRODUCTS AT RISK OF BENZENE CONTAMINATION TO CHILDREN AND TEENAGERS

61. Defendant's BPO Products are widely used by children and teenagers as a standalone treatment or in combination with other BPO Products. Defendant knew that adolescents are the largest users with users as young as 7-10 years old. Defendant recommended that consumers, including children, use the BPO Products one to three times a day, over many months or longer for persistent acne. Defendant knew that some consumers would use the BPO Products for many years starting in their teens. There is no cure for acne. Defendant knew that consumers with chronic acne would use their BPO Products several times a day throughout their lifetime.

62. Defendant aggressively marketed the BPO Products directly to children and teenagers knowing, or they should have known, the BPO Products degrade to benzene under normal use and storage conditions. Many of Defendant's online and print advertisements featured children, teenagers, eye-catching props, music, and colors meant to attract teens and pre-teens, and appeal to their preferences, activities, and interests.

63. Defendant's marketing of BPO Products without mentioning benzene, the risk of

1 benzene exposure, or testing for benzene wase and continues to be misleading, fraudulent, deceptive,
2 and dangerous.

3 **V. PUNITIVE DAMAGES ALLEGATIONS**

4 64. Defendant's conduct was done with malice and reckless disregard for human life.
5 Defendant knew the BPO Products degraded to benzene when exposed to heat under normal
6 consumer use, handling, and storage conditions. Defendant further knew that benzene is a known
7 human carcinogen that is not supposed to be in the BPO Products due to the grave risk of harm to
8 consumers. Defendant disregarded this information and the known risks of benzene exposure and
9 deliberately omitted benzene from the list of ingredients, the BPO Products' labels, and their social
10 media and websites where information about the BPO Products is found. Defendant consciously and
11 deliberately crafted the BPO Products' marketing, labels, packaging, containers, and warnings
12 intending to mislead Plaintiffs, the Class, the Subclasses, and the public, and lead them to believe the
13 BPO Products were safe and carcinogen-free.

14 65. Defendant is a leading pharmaceutical company that marketed itself as an innovator
15 with integrity, while at the same time withholding material information Defendant knew was essential
16 to informed consumer decision making. Defendant knew that, by their conduct, they were robbing
17 Plaintiffs, the Class, the Subclasses, and the public of their right to choose safe products.

18 66. Defendant was on notice of benzene findings in consumer products, which lead to
19 widely publicized product recalls. Defendant was on notice of the FDA's concerns of benzene
20 contamination in drug and consumer products and received the FDA's 2022 directive to test Products
21 for benzene contamination. Defendant disregarded these notices and continued to market and sell the
22 BPO Products to the public without testing them for benzene.

23 67. Defendant knew its decisions and chosen course of conduct was risky and would cause
24 consumers to be exposed to benzene. Defendant's conduct was not by accident, but was deliberate,
25 calculated, and informed. Defendant knew they could sell more BPO Products and earn more money
26 by concealing material human health and safety information. Defendant further knew that testing the
27 BPO Products for benzene would yield findings of benzene requiring recalls and/or a shutdown of
28 causing significant losses of income. Defendant's goals were met not only because of their false and

1 deceptive advertising, labeling, and packaging, but through a comprehensive scheme of aggressive
2 marketing and image branding leading consumers to believe they were consumer conscious retailers
3 dedicated to safety. Defendant's conduct and concealment of material health and safety information
4 was done to further their own monetary gain and with conscious disregard of the Plaintiffs, the Class,
5 the Subclasses, and the public's right to choose safe products. Defendant's conduct was intentional,
6 calculated, blatantly deceptive, unscrupulous, and offensive to consumer health and public policy. To
7 redress the harms caused by Defendant's conduct, Plaintiffs, on behalf themselves, the Class, and
8 Subclasses, seek punitive damages against the Defendant.

9 **VI. PLAINTIFFS' SPECIFIC ALLEGATIONS**

10 68. Plaintiff Grace Navarro is a California resident who places a high priority on health and
11 safety, and on the adverse health consequences of exposure to carcinogens such as benzene. In
12 shopping for drug products for her skin and face, Plaintiff Grace Navarro was particularly concerned
13 about the effectiveness to clean out her pores and avoid breakouts on her face. Plaintiff read the front
14 labeling of the product which encouraged her to purchase the product by Defendants. Based on the
15 statements made by Defendants, their widely recognized name, and lack of information that the BPO
16 Products contained carcinogens such as benzene, Plaintiff believed the BPO Products were safe to put
17 on her skin. Defendants' representations and omissions of human health and safety information were
18 material to Plaintiff.

19 69. Plaintiff Navarro bought Walgreens' Maximum Strength Acne Foaming Wash and used
20 it from June 2022 to September 2022 for breakouts on her face. Plaintiff was unaware when she
21 bought the BPO Products that it was contaminated with benzene or that it could degrade to benzene.
22 Had Defendants been truthful and told Plaintiff she would be exposed to benzene and/or be at
23 increased risk of cancer, she would not have purchased Walgreens' Maximum Strength Acne
24 Foaming Wash.

25 70. Plaintiff Navarro suffered an ascertainable economic loss because of Defendant's
26 statements and misrepresentations in that he bought the BPO Products she would not have bought but
27 for Defendant's statements and misrepresentations.

28 71. Plaintiff Chatham Mullins is a Massachusetts resident who places a high priority on

1 health and safety, and on the adverse health consequences of exposure to carcinogens such as
2 benzene. In shopping for drug products for her skin and face, Plaintiff Chatham Mullins was
3 particularly concerned about the effectiveness to resolve skin inflammation such as redness, cleansing
4 and acne blemishes on her skin and face. Plaintiff read the front labeling of the product which
5 encouraged her to purchase the product by Defendants. Based on the statements made by Defendants,
6 their widely recognized name, and lack of information that the BPO Products contained carcinogens
7 such as benzene, Plaintiff believed the BPO Products were safe to put on her skin. Defendants'
8 representations and omissions of human health and safety information were material to Plaintiff.

9 72. Plaintiff Mullins bought Walgreens' Daily Creamy Benzoyl Peroxide Acne Face Wash
10 and used it 2023 for breakouts on her face. Plaintiff was unaware when she bought the BPO Products
11 that it was contaminated with benzene or that it could degrade to benzene. Had Defendants been
12 truthful and told Plaintiff she would be exposed to benzene and/or be at increased risk of cancer, she
13 would not have purchased Walgreens' Daily Creamy Benzoyl Peroxide Acne Face Wash.

14 73. Plaintiff Mullins suffered an ascertainable economic loss because of Defendant's
15 statements and misrepresentations in that he bought the BPO Products she would not have bought but
16 for Defendant's statements and misrepresentations.

17 **VII. CLASS ACTION ALLEGATIONS**

18 74. Plaintiffs bring this case on behalf of themselves, and all others similarly situated as a
19 Class Action under Rule 23 of the Federal Rules of Civil Procedure. Plaintiffs seek to represent a
20 National Class of consumers who bought the Products, and State Subclasses of consumers from the
21 states identified below. Excluded from this Class is Defendant, their employees, co-conspirators,
22 officers, directors, legal representatives, heirs, successors, and affiliated companies; Class counsel and
23 their employees; and judicial officers and their immediate families as court staff assigned to the case.

24 75. The Class does not seek damages for physical injuries, although Plaintiffs were
25 physically harmed by being exposed to benzene.

26 76. The Class will include a National Class to include all persons who bought for use, and
27 not resale, the Products within the United States.

28 77. The State Subclasses will include all persons who bought for use, and not resale, the

1 Products within California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New
2 York, Nevada, Ohio, Pennsylvania, Rhode Island, and Washington.

3 78. This action has been brought and may be properly maintained as a Class Action under
4 Rule 23 of the Federal Rules of Civil Procedure because there is a well-defined community of interest
5 and the proposed Class meets the class action requirements under Rule 23 of numerosity,
6 commonality, typicality, and adequacy of representation.

7 79. Defendant engaged in a common course of conduct giving rise to the legal rights sought
8 to be enforced by Plaintiffs, on behalf of themselves, and the other Class members. Similar or
9 identical statutory and common law violations, business practices, and injuries are involved.

10 80. **Numerosity.** Plaintiffs believe there are millions of Class members throughout the
11 United States, and there are tens of thousands of Subclass members in each of the listed states, making
12 the Class and state Subclasses so numerous and geographically dispersed that joinder of all members
13 is inconvenient and impracticable.

14 81. **Commonality.** There are questions of law and fact common to all Class and Subclass
15 members that predominate over questions which affect only individual Class members. All Class and
16 Subclass members were deceived and misled by Defendant through the same advertising, online
17 representations, labeling, and packaging, which do not mention benzene and misrepresent the
18 characteristics, ingredients, and safety of the BPO Products. All Class and Subclass members bought
19 Defendant's BPO Products and have suffered an economic loss because of Defendant's deceptions
20 and omissions. Thus, there is a well-defined community of interest in the questions of law and facts
21 common to all Class and Subclass members. Other common questions of law and fact in this dispute
22 include, without limitation:

- 23 a. Whether Defendant's BPO Products degrade to benzene under common distributor and
24 consumer handling, use, and storage conditions.
- 25 b. Whether Defendant tested the BPO Products for benzene before selling them to
26 Plaintiffs, the Class, and the public.
- 27 c. When Defendant knew or should have known the BPO Products degraded to benzene.
- 28 d. When Defendant knew or should have known the BPO Products contain benzene.

- 1 e. Whether Defendant's advertising omitting benzene was deceptive, fraudulent, or unfair.
- 2 f. Whether Defendant's advertising omitting benzene was likely to deceive reasonable
- 3 consumers.
- 4 g. Whether Defendant's conduct violated California's Unfair Competition Law, Bus. &
- 5 Prof. Code § 17200 *et seq.*
- 6 h. Whether Defendant's conduct violated California consumer protection laws.
- 7 i. Whether Defendant's conduct violated Connecticut consumer protection laws.
- 8 j. Whether Defendant's conduct violated Hawaii consumer protection laws.
- 9 k. Whether Defendant's conduct violated Illinois consumer protection laws.
- 10 l. Whether Defendant's conduct violated Massachusetts consumer protection laws
- 11 including Mass. Gen. Laws Ann. Ch. 93A, § 1 *et seq.*
- 12 m. Whether Defendant's conduct violated Maryland consumer protection laws.
- 13 n. Whether Defendant's conduct violated Missouri consumer protection laws including Mo.
- 14 Rev. Stat. § 407, *et seq.*
- 15 o. Whether Defendant's conduct violated Nevada consumer protection laws including
- 16 Deceptive Trade Practice Act, NEV. REV. STATUTES, Title 52, Chapter 598 *et seq.*
- 17 p. Whether Defendant's conduct violated New York consumer protection laws including
- 18 New York Deceptive Trade Practices Law, NY Gen. Bus. §349(a) and NY Gen. Bus. §§
- 19 350 *et seq.*
- 20 q. Whether Defendant's conduct violated Pennsylvania consumer protection laws.
- 21 r. Whether Defendant's conduct violated Rhode Island consumer protection laws.
- 22 s. Whether Defendant's conduct violated Washington's consumer protection laws.
- 23 t. Whether Defendant breached the express and implied warranties they made about the
- 24 BPO Products.
- 25 u. Whether Defendant was unjustly enriched by the Plaintiffs, the proposed Class, and
- 26 Subclasses members' purchase of the BPO Products.
- 27 v. Whether the Plaintiffs, the proposed Class, and Subclasses have been injured and if so,
- 28 what is the proper measure of damages.

1 w. Whether the Plaintiffs, the proposed Class, and Subclasses have the right to economic
2 damages including compensatory, exemplary, and statutory remedies for Defendant's
3 misconduct.

4 x. Whether the Plaintiffs, the proposed Class, and Subclasses have the right to injunctive,
5 declaratory, or other equitable relief and attorneys' fees.

6 82. **Typicality.** Plaintiffs' claims are typical of the claims of the Class and Subclasses
7 because the claims arise from the same course of misconduct by Defendant, *i.e.*, Defendant's false and
8 misleading advertising and their failure to disclose benzene in the Products. The Plaintiffs, and all
9 Class and Subclass members were all exposed to the same uniform and consistent advertising,
10 labeling, and packaging statements Defendant made about the Products. Because of the Defendant's
11 misconduct, Plaintiffs, like all Class members, were damaged and have incurred economic loss
12 because of buying the Products believed to be safe. The claims of the Plaintiffs are typical of Class
13 members.

14 83. **Adequacy.** The Plaintiffs will fairly and adequately represent and protect the interests
15 of all Class and Subclass members. Plaintiffs have no interests antagonistic to the Class or Subclass
16 members. Plaintiffs hired attorneys experienced in the prosecution of consumer Class Actions and
17 Plaintiffs intend to prosecute this action vigorously. Plaintiffs anticipate no difficulty in the
18 management of this litigation as a Class Action.

19 84. Finally, this Class Action is proper under Rule 23(b) because, under these facts, a Class
20 Action is superior to other methods and is the most efficient method for the fair and efficient
21 adjudication of the dispute. The Class and Subclass members have all suffered economic damages
22 because of Defendant's deceptive trade practices, false advertising, and omissions of material health
23 and safety information. Because of the nature of the individual Class and Subclass members' claims
24 and the cost of the Products, few, if any individuals, would seek legal redress against Defendant
25 because the costs of litigation would far exceed any potential economic recovery. Absent a Class
26 Action, individuals will continue to suffer economic losses for which they would have no remedy, and
27 Defendant will unjustly continue their misconduct with no accountability while retaining the profits of
28 their ill-gotten gains. Even if separate cases could be brought by individuals, the resulting multiplicity

1 of lawsuits would cause undue hardship, burden, and expense for the Court and the litigants, as well
2 as create a risk of inconsistent rulings across the country, which might be dispositive of the interests
3 of individuals who are not parties. A Class Action furthers the important public interest of containing
4 legal expenses, efficiently resolving many claims with common facts in a single forum
5 simultaneously, and without unnecessary duplication of effort and drain on critical judicial resources.
6 The Class Action method presents far fewer management difficulties than individual cases filed
7 nationwide and provides the benefit of comprehensive supervision by a single court.

8 **VIII. CAUSES OF ACTION**

9 **A. VIOLATION OF CALIFORNIA’S UNFAIR COMPETITION LAW BUS. & PROF.**
10 **CODE § 17200 et seq., on Behalf of the California Subclass**

11 85. Plaintiffs reallege and incorporates all other paragraphs in this Class Action Complaint
12 and further allege:

13 86. Plaintiffs bring this cause of action on behalf of themselves, and all members of the
14 California Subclass, all of whom are similarly situated consumers.

15 87. California’s Unfair Competition Law, CAL. BUS. & PROF. CODE § 17200, *et seq.*,
16 prohibits “unlawful, unfair, or fraudulent business act or practices” and “unfair, deceptive, untrue or
17 misleading advertising.” Defendant regularly transacts business in California, including in this
18 District, and has engaged in misconduct that has had a direct, substantial, foreseeable, and intended
19 effect of injuring people in California, and in this District.

20 88. Defendant misrepresented their Products in advertising, labels, and containers and
21 misled Plaintiffs, the Subclass, and the public about the ingredients, characteristics, purity, quality,
22 approval, and safety of the Products. Defendant led Plaintiffs, the Subclass, and the public to believe
23 the Products were safe.

24 89. Defendant’s advertising, online representations, labeling, and packaging of the Products
25 were misleading, fraudulent, and deceptive. Defendant knew through the Products’ development,
26 formulation, research, and pre-sale safety and stability testing, the Products were not chemically and
27 physically stable when exposed to common temperature conditions. Defendant knew or should have
28 known the Products formulated benzene under normal and expected consumer use, handling, and

1 storage conditions, and that consumers would be exposed to benzene. Defendant were specifically
2 reminded by the FDA of their obligation to ensure the safety and quality of their Products, including
3 testing them for benzene before selling them to the public, but shirked their duties and continued to
4 market and sell the Products without substantiating their safety, or warning Plaintiffs, the Class, and
5 the public about benzene.

6 90. Defendant omitted material health and safety information, *e.g.*, benzene, from the
7 Products' advertising, label, container, and warnings. Defendant did not tell Plaintiffs and the Class
8 members they would be exposed to benzene, a human carcinogen, during normal and expected
9 handling, use and storage of the Products, even with the Products' container closed.

10 91. Defendant's acts and omissions were likely to deceive reasonable consumers and the
11 public. Reasonable consumers expect to be told about all ingredients in Products. Reasonable
12 consumers further expect that carcinogens in the Products be disclosed. Reasonable consumers further
13 expect that on market drugs to be free of carcinogens, unless told otherwise. Benzene in a widely
14 marketed drug product used by children, teens, and the public is material health information
15 reasonable consumers expect to be told.

16 92. Had Defendant been truthful in their advertising, labeling, packaging, and online
17 statements about benzene in the Products, or the risk of contamination, and the risk of cancer,
18 Plaintiffs and the Class members would not have bought the Products.

19 93. Defendant's acts, omissions, and concealment of material health and safety information
20 are ongoing and continuing to cause harm. Defendant continued to market, advertise, and sell the
21 Products to the public without telling the public about benzene in the Products, or the risk of
22 contamination, and the risk of cancer. Defendant continued to market themselves as responsible drug
23 manufacturers and sellers who sell safe products when they have not tested the Products for benzene
24 or quantified the levels of benzene formed in the Products during normal and expected storage
25 conditions.

26 94. Defendant engaged in these deceptive practices for significant financial gain, which is
27 unfair, unreasonably dangerous to Plaintiffs and the California Subclass members, and not outweighed
28 by any benefit. Omitting and concealing material human health and safety information such as

1 benzene in the Product and the consumers' risk of cancer from the Products is unethical,
2 unscrupulous, and offensive.

3 95. Plaintiffs suffered ascertainable economic losses because of Defendant's misconduct
4 because he bought the Products, he otherwise would not have bought but for Defendant's
5 misrepresentations and affirmations of safety.

6 96. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, and the
7 California Subclass, seek recovery of their economic damages, attorneys' fees, restitution, and all
8 other relief allowable under CAL. BUS. & PROF. CODE § 17200, *et seq.*, including an injunction to
9 enjoin Defendant from continuing their fraudulent and deceptive business practices. The damages
10 sought are ascertainable, uniform to the Class and can be measured and returned to the Class
11 members.

12 **B. VIOLATION OF CALIFORNIA'S CONSUMER LEGAL REMEDIES ACT,**
13 **CAL. CIV. CODE § 1750, et seq., on Behalf of the California Subclass**

14 97. Plaintiffs reallege and incorporates all other paragraphs in this Complaint and further
15 allege:

16 98. Plaintiffs bring this cause of action on behalf of themselves, and the California Subclass
17 members, all of whom are similarly situated consumers within the meaning of CAL. CIV. CODE §
18 1781.

19 99. Defendant's acts and omissions violated California's Consumer Legal Remedies Act,
20 CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived by
21 advertisers, distributors, and sellers like the Defendant. Defendant regularly transacts business in
22 California, including in this District, and has engaged in misconduct that has had a direct, substantial,
23 foreseeable, and intended effect of injuring people in California, and in this District.

24 100. California's Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq. prohibits*
25 unfair methods of competition and unfair or deceptive acts or practices in connection with the sale of
26 consumer goods. Defendant violated several prohibitions of CIV. CODE § 1750(a).

27 101. Defendant violated CAL. CIV. CODE § 1750(a)(2) by representing the source,
28 sponsorship, and approval, of the Products, *e.g.*, the Products were backed by sound scientific

1 principles, that Defendant met its obligations to conduct adequate and meaningful quality and safety
2 testing before selling the Products to the public, and represented the Products only contained the
3 ingredients listed, and were free of carcinogens.

4 102. Defendant violated CAL. CIV. CODE § 1750(a)(3) by representing the affiliation,
5 connection, or association with, or certification by, another *e.g.*, the Products were approved by
6 dermatologists and manufactured in conformity with current good manufacturing practices.

7 103. Defendant violated CAL. CIV. CODE § 1750 (a)(4) by using deceptive representations,
8 *e.g.*, the Products were safe, validated, and supported by the latest research, and free of carcinogens
9 such as benzene.

10 104. Defendant violated CAL. CIV. CODE § 1750(a)(5) by representing the Products have
11 characteristics, ingredients, uses, or benefits, which they do not, *e.g.*, misleading Plaintiffs and the
12 Class members the Products only contained the listed ingredients, did not contain benzene, and did not
13 increase the risk of the consumers' risk of cancer.

14 105. Defendant violated CAL. CIV. CODE § 1750(a)(6) by representing the Products were not
15 deteriorated unreasonably or altered *e.g.*, the Products were pure and had not degraded or formed
16 benzene.

17 106. Defendant violated CAL. CIV. CODE § 1750(a)(7) by representing the Products were
18 pure and of a particular standard or quality, when they are not.

19 107. Defendant violated CAL. CIV. CODE § 1750(a)(9) by advertising the Products with the
20 intent not to sell them as advertised, *e.g.*, the Products were of pure quality, safe, made in conformity
21 with current good manufacturing practices, and not adulterated.

22 108. Had Defendant been truthful in their advertising, labeling, packaging, warnings, and
23 online statements about benzene in the Products and the risk of cancer, Plaintiffs and the California
24 Subclass members would not have bought the Products. Benzene, a human carcinogen, in a widely
25 marketed and available consumer drug product, is material health and safety information Defendant
26 knew Plaintiffs, the Class members, and the public would want to know. The Defendant's omission of
27 this material information was common to Plaintiffs and all Subclass members and made to Plaintiffs
28 and all Subclass members uniformly through common advertising, online representations, labeling,

1 and packaging.

2 109. Defendant's acts, omissions, and concealment of material health and safety information
3 are ongoing and continuing to cause harm. Defendant continued to market, advertise, and sell the
4 Products to the public without telling the public about benzene in the Products and the risk of cancer.
5 Defendant continues to market themselves as responsible drug manufacturers and sellers who sell safe
6 products when they have not quantified the levels of benzene in and created in the Products during
7 normal and expected storage conditions.

8 110. Defendant engaged in these deceptive practices for significant financial gain, which is
9 unfair, unreasonably dangerous to Plaintiffs and the Subclass members, and not outweighed by any
10 benefit. Omitting and concealing material human health and safety information such as the
11 consumers' risk of cancer from exposure to the Products is unethical, unscrupulous, and offensive.

12 111. Plaintiffs suffered ascertainable economic losses because of Defendant's misconduct
13 because he bought the Products, she otherwise would not have but for Defendant's misrepresentations.

14 112. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves and the
15 California Class seek recovery of their economic damages, attorneys' fees, punitive damages,
16 restitution, and all other relief allowable under CAL. CIV. CODE § 1750, *et seq.*, including an injunction
17 to enjoin Defendant from continuing their fraudulent business practices. The damages sought are
18 ascertainable, uniform to the Subclass and can be measured and returned to the Subclass members.

19 **C. FALSE ADVERTISING UNDER VARIOUS STATE STATUTES, Individually**
20 ***and on behalf of the California, Hawaii and New York Subclasses***

21 113. Plaintiffs reallege and incorporates all other paragraphs in this Complaint and further
22 allege:

23 114. Plaintiffs bring this cause of action on behalf of themselves, and all members of the
24 California, Hawaii, and New York Subclasses, all of whom are similarly situated consumers.

25 115. Defendant develops, tests, selects, markets and/or sells the BPO Products throughout
26 the United States in its stores and through eCommerce websites. Defendant knew through the
27 Products' development, formulation, and selection, the Products were not chemically stable when
28 exposed to certain expected and normal environmental and storage conditions and formed benzene, as

1 a toxic byproduct. Despite this knowledge, Defendant did not mention benzene in the Products’
2 advertising, ingredient lists, labels, containers, or warnings. Defendant did not tell Plaintiffs, and the
3 Subclass members they would be exposed to benzene, a human carcinogen, during normal and
4 expected handling, use and storage of the Products, even with the Products’ containers closed.

5 116. Benzene, a human carcinogen, in a widely marketed and available consumer drug
6 product, is material health and safety information Defendant knew Plaintiffs, and the Subclass
7 members would want to know. Defendant not only omitted this material human health and safety
8 information from advertising, online representations, blogs, labeling, packaging, and warnings, but
9 aggressively marketed itself as consumer conscious, a market leader, and company committed to
10 consumer safety. Defendant’s brand notoriety, market share, and affirmations of safety misled
11 Plaintiffs, and the Subclass members, leading them to believe the Products were tested, verified, and
12 safe. Defendant further marketed the Products touting the approval of dermatologists, who were not
13 aware of the presence of benzene in the Products and of Defendant’s refusal to conduct adequate and
14 meaningful testing before marketing and selling the Products to the public and following the FDA’s
15 2022 alert to specifically look for benzene.

16 117. Defendant’s acts and omissions constitute false advertising. Defendant advertised the
17 Products with the intent not to sell them as advertised. Reasonable consumers, including Plaintiffs and
18 the Subclass members, exposed to Defendant advertising would believe the Products were safe,
19 verified, and free of benzene.

20 118. Defendant’s false and misleading advertising violated California’s False Advertising
21 Law, Bus. & Prof. Code § 17500 *et seq.*, which prohibits Defendant from disseminating statements
22 “which are untrue or misleading, and which are known, or which by the exercise of reasonable care
23 should be known, to be untrue or misleading.” Defendant knew or should have known the Products
24 formed benzene under normal, handling, use, and storage conditions but did not disclose this to
25 Plaintiffs and the Class and Subclass members. Defendant knew or should have known the Products
26 were not chemically stable when exposed to certain normal and expected environmental conditions.

27 119. Defendant’s false and misleading advertising violated Hawaii’s False Advertising Law,
28 HI REV. STAT. § 708-871. Defendant knowingly or recklessly made false and misleading statements in

1 the Products' advertising to the public.⁶⁵ Defendant further advertised the Products with the intent not
2 to sell them as advertised and misrepresented the ingredients, quality, purity, safety, and character of
3 the Products.

4 120. Defendant's false and misleading advertising violated New York's General Business
5 Law § 350 *et seq.* ("GBL § 350"), which prohibits "[f]alse advertising in the misconduct of any
6 business, trade or commerce or in the furnishing of any service" in New York. Under GBL § 350,
7 "false advertising" includes "advertising, including labeling, of a commodity . . . if such advertising is
8 misleading in a material respect." Defendant violated GBL § 350 by advertising and selling the
9 Products without disclosing material health and safety information, *e.g.*, benzene and the consumers
10 risk of cancer from benzene. Defendant's false and misleading advertising was directed at consumers,
11 the New York Subclass members, and the public, and caused consumer injury and harm to the public
12 interest.

13 121. Had Defendant been truthful in their advertising, online representations, labeling, and
14 packaging about benzene, Plaintiffs, and the Subclass members would not have bought the Products.

15 122. Plaintiffs, on behalf of themselves, and the California, Hawaii, and New York Subclass
16 members suffered ascertainable economic losses because of Defendant's misconduct because they
17 bought the Products, they otherwise would not have but for Defendant's material misrepresentations.

18 123. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, and the
19 California, Hawaii, and New York Subclass members, seek recovery of their economic damages,
20 attorneys' fees, punitive damages, restitution, and all other relief allowable by law, including an
21 injunction to enjoin Defendant from continuing their fraudulent business practices. The damages
22 sought are ascertainable, uniform, and can be measured and returned.

23 ///

24
25
26 ⁶⁵ HI REV STAT § 708-871, False Advertising: (1) A person commits the offense of false advertising if, in
27 connection with the promotion of the sale of property or services, the person knowingly or recklessly makes or
28 causes to be made a false or misleading statement in any advertisement addressed to the public or to a
substantial number of persons. (2) "Misleading statement" includes an offer to sell property or services if the
offeror does not intend to sell or provide the advertised property or services: (a) At the price equal to or lower
than the price offered; or (b) In a quantity sufficient to meet the reasonably- expected public demand unless
quantity is specifically stated in the advertisement; or (c) At all.

1 **D. DECEPTIVE TRADE PRACTICES UNDER VARIOUS STATE STATUTES,**
2 *Individually and on Behalf of the California, Connecticut, Hawaii, Illinois,*
3 *Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode*
4 *Island, and Washington Subclasses*

5 124. Plaintiffs reallege and incorporates all other paragraphs in this Complaint and further
6 allege:

7 125. Plaintiffs bring this cause of action on behalf of themselves, and all members of the
8 Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania,
9 Ohio, Rhode Island, and Washington Subclasses, all of whom are similarly situated consumers.

10 126. Defendant's acts and omissions constitute deceptive business practices in violation of
11 state deceptive trade practices laws.

12 127. Defendant represented the BPO Products had characteristics, uses, and benefits, they
13 did not, *e.g.*, Defendant represented the BPO Products were pure, of good quality, safe, and only
14 contained the ingredients disclosed.

15 128. Defendant represented the BPO Products were not deteriorated or altered, when they
16 knew, or should have known, the BPO Products degraded to benzene under normal and expected use,
17 handling, and storage conditions.

18 129. Defendant represented the BPO Products contained only the ingredients listed on
19 Defendant's websites, advertising, labels, and containers. Defendant did not disclose to Plaintiffs, the
20 Class and Subclass members, and the public the BPO Products were at risk of benzene contamination.

21 130. Defendant advertised the BPO Products with the intent not to sell them as advertised.

22 131. Defendant's acts and omissions violated California's Consumer Legal Remedies Act,
23 CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived
24 by advertisers, distributors, and sellers like the Defendant.

25 132. Defendant's acts and omissions violated Connecticut Unfair Trade Practices Act, CONN.
26 GEN STAT. ANN., § 42- 110, *et seq.*, which broadly prohibits Defendant from engaging in unfair
27 methods of competition and unfair or deceptive acts or practices in the conduct of any trade
28 or commerce such as those committed by Defendant and alleged in this Class Action.

 133. Defendant's acts and omissions violated Hawaii's Uniform Deceptive Trade Practice

1 Act, HAW. REV. STAT. §481-A3 because Defendant: (1) caused the likelihood of confusion or of
2 misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2)
3 represented the Products had characteristics, ingredients, or benefits, they did not; (3) represented the
4 Products were not deteriorated or altered, when they were; (4) represented the Products were of a
5 particular standard or quality when they were not; and (5) advertised the Products with the intent not
6 to sell them as advertised.

7 134. Defendant's acts and omissions violated Illinois' Consumer Fraud and Deceptive
8 Business Practices Act, 815 ILCS 505/1 *et seq.* Defendant's used deception, fraud, false pretense,
9 false promises, and omitted material health and safety information about the Products' degradation to
10 benzene, and/or contamination with benzene, which Defendant intended the Illinois Subclass
11 members to rely upon.

12 135. Defendant's acts and omissions violated Maryland's Unfair or Deceptive Trade
13 Practices Act, MD. COM. CODE, Title 13, Subtitle 3, §13-301 because Defendant: (1) represented the
14 Products had characteristics, ingredients, uses, and benefits, they did not; (2) represented the Products
15 were not deteriorated or altered, when they were; (3) represented the Products were of a particular
16 standard or quality, when they were not. Defendant's representations about the Products' ingredients,
17 and omission of benzene were misleading, deceptive, incomplete, and not truthful in violation of
18 Maryland's Unfair or Deceptive Trade Practices Act.

19 136. Defendant's acts and omissions violated Massachusetts consumer protection law, MASS.
20 GEN. LAWS ANN. Ch. 93A, § 1 *et seq.*, which broadly prohibits unfair and deceptive trade practices
21 such as those committed by Defendant and alleged in this Class Action.

22 137. Defendant's acts and omissions violated the Missouri Merchandising Practices Act, MO.
23 REV. STAT. § 407, *et seq.*, which prohibits the use of deception, fraud, misrepresentations, or unfair
24 practices by a business, *e.g.*, marketing Products as safe, approved, tested, and only containing the
25 listed ingredients. Missouri's law further prohibits the suppression or omission of material facts such
26 as the Products' degradation to benzene.

27 138. Defendant's acts and omissions violated N.Y. GEN. BUS. LAW § 349, which prohibits
28 Defendant from engaging in deceptive, unfair, and misleading acts and practices such as those

1 committed by Defendant and alleged in this Class Action. Defendant's misrepresentations and
2 omissions caused consumer injury and harm to the public interests of protecting public health and the
3 public's right to know about any harmful constituents in the Products.

4 139. Defendant's acts and omissions violate Nevada Deceptive Trade Practice Act, NEV.
5 REV. STATUTES, Title 52, Chapter 598 *et seq.* which prohibits Defendant from making false statements
6 about their Products and advertising the Products without the intent to sell them as advertised.

7 140. Defendants' acts and omissions violated Ohio's Consumer Sales Practices Act, OHIO
8 REV. CODE ANN. § 1345.01, *et seq.* which prohibits sales practices that are deceptive, unfair, or
9 unconscionable, and Ohio's Deceptive Trade Practices Act, OHIO REV. CODE ANN. § 4165 *et seq.*

10 141. Defendant's acts and omissions violated Pennsylvania's Unfair Trade Practices and
11 Consumer Protection Law, 73 P.S. §§201-1 *et seq.* because Defendant: (1) caused the likelihood of
12 confusion or of misunderstanding as to the source, sponsorship, approval, or certification of the
13 Products; (2) used deceptive representations about the Products; (3) represented the Products had
14 characteristics, ingredients, or benefits, they did not; (3) represented the Products were not
15 deteriorated or altered, when they were; (4) represented the Products were particular standard or
16 quality when they are not; and (5) advertised the Products with the intent not to sell them as
17 advertised.

18 142. Defendant's acts and omissions violated Rhode Island's Deceptive Trade Practices Act,
19 R.I. GEN. LAWS § 6- 13.1- 5.2(B), *et seq.* because Defendant: (1) caused likelihood of confusion or of
20 misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2) used
21 deceptive representations in connection with the Products; (3) represented the Products had
22 sponsorship, approval, characteristics, ingredients, uses, benefits, they did not; (4) represented the
23 Products were not deteriorated or altered, when they were; (5) represented the Products were of a
24 particular standard, quality, or grade, when they were not; and (6) advertised the Products with the
25 intent not to sell them as advertised.

26 143. Defendant's acts and omissions violated Washington's Consumer Protection Act,
27 WASH. REV. CODE § 19.86.010, *et seq.*, which broadly prohibits Defendant from engaging in unfair
28 methods of competition and unfair or deceptive acts or practices in the conduct of any trade

1 or commerce.⁶⁶ Defendant's concealment of material health and safety information about the
2 Products, which they knew or should have known, was injurious to the public interests of protecting
3 public health and the public's right to know about any harmful constituents in the Products.
4 Defendant's conduct caused harm to the Plaintiffs, the Washington subclass members, and members
5 of the public who bought the Products without knowing they degraded to benzene. Defendant's
6 conduct has the capacity to cause harm to other persons who buy the Products.

7 144. Had Defendant been truthful in their advertising, labeling, and packaging of the
8 Products and not omitted material health and safety information about benzene in and formed from the
9 Products, Plaintiffs, the Class, and Subclass members would not have bought the Products.

10 145. Defendant's acts and omissions and violations of the state consumer protection statutes
11 are ongoing and continuing to cause harm.

12 146. Plaintiffs, on behalf of themselves, and the Subclasses suffered an ascertainable
13 economic loss because of Defendant's misconduct because they bought the Products, they would not
14 have bought but for Defendant's misrepresentations.

15 147. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, and the
16 Subclasses seek recovery of their economic damages, attorneys' fees, punitive damages, and all other
17 relief allowable under the law. The damages sought are ascertainable, uniform and can be measured
18 and returned.

19 **E. BREACH OF EXPRESS WARRANTY, *Individually and on Behalf of the***
20 ***Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois,***
21 ***Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode***
Island, and Washington State Subclasses

22 148. Plaintiffs reallege and incorporates all other paragraphs in this Complaint and further
23 allege:

24 149. Plaintiffs bring this cause of action on behalf of themselves, and all members of the
25 National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri,
26 New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are

27 _____
28 ⁶⁶ Under § 19.86.090, Washington consumers harmed by such practices may recover actual damages, the costs of the suit, including reasonable attorney's fees, and the court may, in its discretion, increase the award of damages to an amount up to three times the actual damages sustained.

1 similarly situated consumers.

2 150. The Uniform Commercial Code § 2-313 provides that an affirmation of fact or promise
3 made by the seller to the buyer which relates to the goods and becomes part of the basis of the bargain
4 creates an express warranty that the goods shall conform to the promise. Defendant advertised and
5 sold the Products as safe, pure, of good quality, and only containing the listed ingredients.
6 Defendant's advertising, labels, containers, packaging, advertising, and online statements did not
7 mention benzene, leading consumers to believe the Products were safe for their ordinary use.
8 Defendant's affirmations were uniformly made to Plaintiffs, the Class, and Subclass members by
9 Defendant in the Products' advertising, labeling, packaging, and online statements and were part of
10 the basis of the bargain between Defendant, the Plaintiffs, the Class, and Subclass members.

11 151. Defendant's affirmations and promises are unlawful. When Defendant marketed,
12 distributed, and sold the Products, Defendant knew, or should have known, the Products degraded to
13 benzene under normal and expected use, handling, and storage conditions. Defendant knew, or should
14 have known, the Products formed benzene and therefore did not conform to Defendant's express
15 representations and warranties to consumers. Plaintiffs, the Class, and Subclass members purchased
16 the Products in reasonable reliance on Defendant's statements.

17 152. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, the Class and
18 Subclass members seek recovery of their economic damages, attorneys' fees, punitive damages,
19 restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from
20 continuing their fraudulent business practices. The damages sought are ascertainable, uniform to the
21 Class and Subclasses and can be measured and returned to the Class and Subclass members.

22 **F. BREACH OF IMPLIED EXPRESS WARRANTY, *Individually and on Behalf of*
23 *the Nationwide Class and on Behalf of the California, Hawaii, Illinois, Maryland,*
24 *Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and*
*Washington Subclasses***

25 153. Plaintiffs reallege and incorporates all other paragraphs in this Complaint and further
26 allege:

27 154. Plaintiffs bring this cause of action on behalf of themselves, and all members of the
28 National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri,

1 New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are
2 similarly situated consumers.

3 155. Defendant, as sellers of the Products, also made implied warranties including
4 warranting the Products were of the same quality and purity represented on the labels, in advertising,
5 and on Defendant's websites, were fit for the ordinary purpose of the Products and conformed to the
6 promises made on the containers, labels, advertising, and websites that all ingredients were listed, and
7 all warnings given.

8 156. Defendant advertised their Products as safe, when they knew, or should have known,
9 the Products degraded to benzene. Defendant did not list benzene as an ingredient or contaminant
10 anywhere on the Products or advertising. The Products are not of the quality and purity represented by
11 Defendant because the Products degrade to benzene under normal use, handling, and storage
12 conditions.

13 157. Defendant did not tell Plaintiffs or the Class or Subclass members the Products were not
14 fit for their ordinary use because the Products, as advertised and sold by Defendant, degraded to
15 benzene under normal and expected handling, use, and storage.

16 158. Defendant's affirmations that the Products were safe for use were uniformly made to
17 the Plaintiffs and the Class members in the Products' advertising, labeling, and packaging, and on
18 Defendant's websites, which were part of the basis of the bargain.

19 159. Plaintiffs, the Class, and Subclass members purchased the Products in reasonable
20 reliance on Defendant's statements, affirmations, and omissions of material health and safety
21 information.

22 160. Defendant's acts and omissions are ongoing and continuing to cause harm.

23 161. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, the Class and
24 Subclass members, seek recovery of their actual damages, injunctive relief, attorneys' fees, punitive
25 damages, and all other relief allowable under the law. The damages sought are uniform to the Class
26 and Subclasses and the actual damages can be measured and returned to consumers who bought
27 Defendant's Products.

28 ///

1 **G. UNJUST ENRICHMENT, *Individually and on Behalf of the Nationwide Class and***
2 ***on Behalf of the California, Hawaii, Illinois, Maryland, Massachusetts, Missouri,***
3 ***New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses***

4 162. Plaintiffs reallege and incorporates all other paragraphs in this Complaint and further
5 allege:

6 163. Plaintiffs brings this cause of action on behalf of themselves, and all members of the
7 National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri,
8 New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are
9 similarly situated consumers.

10 164. Defendant has unjustly profited from their deceptive business practices and kept the
11 profits from Plaintiffs and the Class and Subclass members who purchased the Products.

12 165. Defendant requested and received a measurable economic benefit at the expense of
13 Plaintiffs, the Class, and Subclass members as payment for the Products. Defendant accepted the
14 economic benefits from Plaintiffs, the Class, and Subclass members knowing the economic benefit
15 received was based on deception and omission of material human health and safety information.

16 166. There is no utility in Defendant's misconduct and Defendant's enrichment from the
17 misconduct is unjust, inequitable, unconscionable, and against the strong public policy to protect
18 consumers against fraud.

19 167. Because of Defendant's misconduct, Plaintiffs, on behalf of themselves, the Class and
20 Subclass members, and the public seeks recovery of their actual damages, disgorgement of profits,
21 injunctive relief, attorneys' fees, punitive damages, and all other relief allowable under the law. The
22 damages sought are uniform to the Class and Subclasses and the actual damages can be measured and
23 returned to consumers who bought Defendant's Products.

24 **IX. PRAYER FOR RELIEF**

25 168. WHEREFORE, Plaintiffs pray for judgment against Defendant:

26 169. That the Court determine this action may be maintained as a Class Action under Rule
27 23(a) and (b)(1), (2) and (3) of the Federal Rules of Civil Procedure;

- 28 a. That Defendant's misconduct be adjudged to have violated the state consumer
protection laws identified herein;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

- b. That injunctive and declaratory relief be awarded against Defendant, including but not limited to an order prohibiting Defendant from engaging in the alleged misconduct;
- c. That Defendant be ordered to disgorge profits and revenues derived from their course of misconduct and that such unjust enrichment be restored to the class and or distributed cy pres as the Court shall deem just and equitable;
- d. That Plaintiffs recover all compensatory damages and other damages sustained by Plaintiffs;
- e. That Plaintiffs recover punitive damages as allowed by law;
- f. That Plaintiffs recover all statutory damages as allowed by law;
- g. That Plaintiffs recover their attorneys’ fees and all costs of suit;
- h. That Plaintiffs recover all Statutory pre-judgment and post-judgment interest on any amounts; and
- i. That all further relief as this Court may deem just and proper be granted.

X. DEMAND FOR JURY TRIAL

166. Demand is made for a jury trial.

Dated: March 8, 2024

WISNER BAUM LLP

By: /s/ R. Brent Wisner
 R. Brent Wisner, Esq. (SBN: 276023)
rbwisner@wisnerbaum.com
 11111 Santa Monica Blvd, #1750
 Los Angeles, CA 90025
 Telephone: (310) 207-3233
 Facsimile: (310) 820-7444

Attorney for Plaintiffs

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS
GRACE NAVARRO and CHATHAM MULLINS, on behalf of themselves, and all others similarly situated, and the general public
(b) County of Residence of First Listed Plaintiff Fresno
(c) Attorneys (Firm Name, Address, and Telephone Number)
R. Brent Wisner (rbwisner@wisnerbaum.com) WISNER BAUM, LLP, 11111 Santa Monica Blvd., #1750, Los Angeles, CA 90025 (310) 207-3233

DEFENDANTS
WALGREENS BOOTS ALLIANCE, INC. and DOES 1 to 50, Inclusive
County of Residence of First Listed Defendant Lake
NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.
Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)
1 U.S. Government Plaintiff
2 U.S. Government Defendant
3 Federal Question (U.S. Government Not a Party)
4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)
PTF DEF
Citizen of This State [X] 1 [] 1
Citizen of Another State [] 2 [] 2
Citizen or Subject of a Foreign Country [] 3 [] 3
Incorporated or Principal Place of Business In This State [] 4 [] 4
Incorporated and Principal Place of Business In Another State [] 5 [X] 5
Foreign Nation [] 6 [] 6

IV. NATURE OF SUIT (Place an "X" in One Box Only) Click here for: Nature of Suit Code Descriptions.

Table with 5 columns: CONTRACT, REAL PROPERTY, TORTS, CIVIL RIGHTS, PRISONER PETITIONS, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES. Includes various legal categories like Personal Injury, Real Property, Labor, etc.

V. ORIGIN (Place an "X" in One Box Only)
[X] 1 Original Proceeding
[] 2 Removed from State Court
[] 3 Remanded from Appellate Court
[] 4 Reinstated or Reopened
[] 5 Transferred from Another District (specify)
[] 6 Multidistrict Litigation - Transfer
[] 8 Multidistrict Litigation - Direct File

VI. CAUSE OF ACTION
Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
28 U.S. Code § 1332(a)
Brief description of cause:
Diversity of citizenship

VII. REQUESTED IN COMPLAINT:
[X] CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$ CHECK YES only if demanded in complaint: JURY DEMAND: [X] Yes [] No

VIII. RELATED CASE(S) IF ANY (See instructions): JUDGE DOCKET NUMBER

DATE Mar 8, 2024 SIGNATURE OF ATTORNEY OF RECORD /s/ R. Brent Wisner

FOR OFFICE USE ONLY
RECEIPT # AMOUNT APPLYING IFP JUDGE MAG. JUDGE

Case 1:24-cv-00290-SKO Document 1-1 Filed 03/08/24 Page 2 of 2
INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- I.(a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence.** For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys.** Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".
- II. Jurisdiction.** The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below.
 United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.
 Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.
 Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)
- III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- IV. Nature of Suit.** Place an "X" in the appropriate box. If there are multiple nature of suit codes associated with the case, pick the nature of suit code that is most applicable. Click here for: [Nature of Suit Code Descriptions](#).
- V. Origin.** Place an "X" in one of the seven boxes.
 Original Proceedings. (1) Cases which originate in the United States district courts.
 Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441.
 Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.
 Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date.
 Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.
 Multidistrict Litigation – Transfer. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407.
 Multidistrict Litigation – Direct File. (8) Check this box when a multidistrict case is filed in the same district as the Master MDL docket.
PLEASE NOTE THAT THERE IS NOT AN ORIGIN CODE 7. Origin Code 7 was used for historical records and is no longer relevant due to changes in statute.
- VI. Cause of Action.** Report the civil statute directly related to the cause of action and give a brief description of the cause. **Do not cite jurisdictional statutes unless diversity.** Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service.
- VII. Requested in Complaint.** Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P.
 Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction.
 Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases.** This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.